循環腫瘤來源的無細胞DNA市場：按腫瘤類型、癌症類型、技術、應用和地區分類

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

循環腫瘤來源的無細胞DNA市場預計在2026年達到113.5億美元，預計2033年將達到486.2億美元。預計從2026年到2033年，其複合年成長率將達到23.1%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	113.5億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	23.10%	預計金額（2033 年）	486.2億美元

循環腫瘤DNA (ctDNA) 指的是來自惡性細胞或腫瘤的DNA，這些DNA在血液中循環。大部分DNA存在於細胞核內。隨著腫瘤的生長，細胞死亡並被新的細胞取代。死亡細胞分解後，會將其內容物（包括DNA）釋放到血液中。 ctDNA通常是短的DNA片段，長度通常小於200個核苷酸。 ctDNA的含量因人而異，並受腫瘤類型、位置以及（對於惡性腫瘤而言）疾病分期的影響。循環腫瘤DNA (ctDNA) 通常包含可能有助於癌症檢測的遺傳變異。 ctDNA的其他重要用途包括預後預測、監測治療效果和評估腫瘤體積。當新的癌症檢測方法能夠在癌症早期、無症狀階段（此時治癒率最高）檢測到癌症時，其臨床效用才能最大化。循環腫瘤DNA分析有助於癌症的早期發現，也可用於提供分子標靶治療。

市場動態

預計在預測期內，市場成長將主要得益於市場領導者擴大採用內部成長策略，例如推出新產品以拓展產品系列。例如，2022年7月，新一代分子診斷公司BillionToOne Inc.宣布推出首款癌症液態生物檢體產品Northstar Select和Northstar Response。目前，這些產品已在部分學術癌症中心投入研究使用。 Northstar Select是一款全面的泛腫瘤體細胞突變譜分析試劑盒。該試劑盒利用BillionToOne的專有分子計數技術－定量計數模板（QCTs），在識別具有治療意義的突變方面實現了卓越的檢測極限。而Northstar Response則是一款基於甲基化的、組織非依賴性的治療反應監測檢測方法。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球循環腫瘤衍生無細胞 DNA 市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球循環無細胞腫瘤 DNA 市場中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

Biocept, Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
KURABO INDUSTRIES LTD
PerkinElmer chemagen Technologie GmbH
Biodesix
Guardant Health
QIAGEN
Sequenom, Inc.
Agilent Technologies, Inc.
Fluxion Biosciences Inc.
Natera, Inc.
Agena Bioscience, Inc.
Paragon Genomics, Inc.
Lucence Health Inc.
Eurofins Genomics
Thermo Fisher Scientific

第10章

調查方法
關於本公司

簡介目錄

Product Code: CMI5819

Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 11.35 Bn in 2026 and is expected to reach USD 48.62 Bn by 2033, growing at a compound annual growth rate (CAGR) of 23.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 11.35 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	23.10%	2033 Value Projection:	USD 48.62 Bn

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

Global Circulating Cell-Free Tumor DNA Market, By Tumor Type (Revenue, USD Bn, 2021 - 2033)
Malignant Tumors
Precancerous Tumors
Global Circulating Cell-Free Tumor DNA Market, By Cancer Type (Revenue, USD Bn, 2021 - 2033)
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
Global Circulating Cell-Free Tumor DNA Market, By Technology (Revenue, USD Bn, 2021 - 2033)
PCR
Massively Parallel Sequencing
Single Nucleotide Polymorphism
Global Circulating Cell-Free Tumor DNA Market, By Application (Revenue, USD Bn, 2021 - 2033)
Cancer Diagnosis
Targeting Therapeutics
Prognosis Indication
Global Circulating Cell-Free Tumor DNA Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Biocept, Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
KURABO INDUSTRIES LTD
PerkinElmer chemagen Technologie GmbH
Biodesix
Guardant Health
QIAGEN
Sequenom, Inc.
Agilent Technologies, Inc.
Fluxion Biosciences Inc.
Natera, Inc.
Agena Bioscience, Inc.
Paragon Genomics, Inc.
Lucence Health Inc.
Eurofins Genomics
Thermo Fisher Scientific

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Tumor Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Malignant Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Precancerous Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

5. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Technology, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
PCR
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Massively Parallel Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Single Nucleotide Polymorphism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Application, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Targeting Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Prognosis Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Region, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Quest Diagnostics Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
KURABO INDUSTRIES LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PerkinElmer chemagen Technologie GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biodesix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sequenom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fluxion Biosciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agena Bioscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Paragon Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lucence Health Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies